CCL22 and neoplasm: Although these data provide important proof of concept that therapeutically activating CCL22 could be effective and feasible, we are well aware that CCL22 is elevated in the tumor tissues, which is linked to Treg recruitment and contributes to an immunosuppressive environment for tumors (82–84).